XOOMAR
Get a free API key

Starling Oncology (STLN)

Starling Oncology on one page: short interest, daily short volume, fails to deliver, 13F holders, earnings dates and insider trades. Listed on Nasdaq.

Download CSV

6.5M

Short interest

settlement 2026-10-15

5.6

Days to cover

+1.3 days vs prior

70.5%

Short share of volume

2026-11-02

348

Fails to deliver

settlement 2026-10-05

Thu 12 Nov

Next earnings

estimated date

-$1.9M

Insider flow, 90 days

1 buys, 1 sells

As of 2026-11-02.

Short interest

FINRA, twice a month. The newest 5 settlements in the table. JSON

As of 15 October 2026, short interest in STLN is 6,535,739 shares, down 518,181 shares over the last month. At the reported average volume of 1.2M shares a day that is 5.6 days to cover.

SettlementShares shortChangeAvg daily volumeDays to cover
2026-10-156,535,739-3.8%1,162,6985.62
2026-09-306,793,070-3.7%1,576,7874.31
2026-09-157,053,920+3.5%959,3657.35
2026-08-316,816,792-1.0%1,220,8235.58
2026-08-146,884,302-3.8%1,958,8373.51

Daily short volume

FINRA Reg SHO, the last 30 sessions. JSON

As of 2 November 2026, the short share of STLN volume is 70.5%, up 16.9 points over the last five sessions. Over the last 30 readings it ranged from 30.3% (8 October 2026) to 81.0% (21 October 2026). The latest reading is 14.7 points above the 30-session average of 55.8%, on 610K shares reported.

DateShort volumeTotal volumeShort shareExempt
2026-11-02430K610K70.5%0
2026-10-30399K590K67.6%17,961
2026-10-29256K407K62.9%0
2026-10-28228K368K62.0%26
2026-10-27300K480K62.5%48
2026-10-26441K824K53.5%1,536
2026-10-23231K317K72.8%1,917
2026-10-22238K367K65.1%3,851
2026-10-21535K660K81.0%3,798
2026-10-20214K366K58.4%11
2026-10-19280K384K73.0%15
2026-10-16323K636K50.7%1,046
2026-10-15267K489K54.5%0
2026-10-14219K492K44.5%0
2026-10-13203K556K36.4%8
2026-10-12284K426K66.6%0
2026-10-09289K547K52.8%813
2026-10-08157K518K30.3%1
2026-10-07184K394K46.6%1,164
2026-10-06226K444K51.0%0
2026-10-05202K662K30.6%200
2026-10-02152K383K39.7%368
2026-10-01187K411K45.6%150
2026-09-30148K249K59.3%0
2026-09-29180K315K57.3%0
2026-09-28211K342K61.7%10,113
2026-09-25211K397K53.3%0
2026-09-24350K761K46.0%3,728
2026-09-23302K480K62.9%1,493
2026-09-22229K419K54.7%0

Fails to deliver

SEC, the last 13 settlement dates with a fail. JSON

As of 5 October 2026, the fails-to-deliver balance in STLN is 348 shares, down 6 shares over the last settlement date. Over the last 13 readings it ranged from 3 shares (25 August 2026) to 40,712 shares (13 August 2026). The latest reading sits at the bottom of that range.

SettlementShares failedPriceValue
2026-10-05348$6.35$2K
2026-09-23354$7.05$2K
2026-09-1110$6.20$62
2026-08-3138$6.17$234
2026-08-253$6.13$18
2026-08-241,900$6.47$12K
2026-08-2044$6.66$293
2026-08-17156$6.45$1K
2026-08-1438,286$6.26$240K
2026-08-1340,712$6.32$257K
2026-08-1240,337$6.20$250K
2026-08-1140,303$6.16$248K
2026-08-1039,955$6.41$256K

Insider trades

SEC Form 4, newest first. JSON

Over the last 90 days STLN insiders reported 1 open-market buy ($78K) against 1 sell ($1.9M), so the dollar flow leans toward selling. Latest filing: Hively Brad (Director) on 2026-08-21.

DateInsiderTitleTypeSharesPriceValueOwned after
2026-08-21Hively BradDirectorSell299K$6.51$1.9M412K
2026-08-14Chernett Jorey10% ownerBuy12K$6.54$78K10.7M

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

13F holders

Tracked managers holding STLN at their latest 13F. JSON

5 of the 30 tracked managers held STLN at their latest 13F, $16.7M in total at quarter-end prices. Renaissance Technologies is the largest at $7.4M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 1 cut.

FundQuarterSharesValueOf portfolioChange in shares
Renaissance Technologies2026-06-301.4M$7.4M0.01%+463K
Citadel Advisors2026-06-30894K$4.9M0.00%+286K
Two Sigma Investments2026-06-30669K$3.6M0.00%+361K
Millennium Management2026-06-3097K$526K0.00%-35K
AQR Capital Management2026-06-3049K$264K0.00%+4K

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

What this page is

Starling Oncology in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.

This page follows Starling Oncology (STLN), SEC CIK 1799191, listed on Nasdaq. The cross-market tables live on the short interest and insider transactions hubs.

Source and updates

Short interest
FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
Daily short volume
FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
Fails to deliver
SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-05.JSON and CSV
13F holders
SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
Earnings dates
SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
Insider trades
SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-08-21.JSON and CSV
Company record
EDGAR filing index for CIK 1799191Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits
10 requests a minute without a key, 30 with a free key from a free account.

How to read it

  • Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
  • Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
  • Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Other company pages

Datasets

Frequently Asked Questions

How much of STLN is sold short?
6,535,739 shares were held short at the 2026-10-15 settlement, 5.6 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is STLN's daily short volume?
On 2026-11-02, 429,504 of the 609,687 STLN shares reported to FINRA were sold short, 70.5% of the day's reported volume. Short volume is a flow for one day, not a position.
Does STLN have fails to deliver?
The SEC's latest file shows 348 STLN shares failed to deliver at settlement 2026-10-05. Fails are reported per settlement date and published twice a month with a lag.
Are STLN insiders buying or selling?
Over the last 90 days STLN insiders reported 1 open-market buy ($78K) against 1 sell ($1.9M), so the dollar flow leans toward selling. Latest filing: Hively Brad (Director) on 2026-08-21.
Which tracked 13F managers own STLN?
5 of the 30 tracked 13F managers held STLN shares at their latest filing, $16.7M in all. The largest: Renaissance Technologies (1.4M shares, $7.4M), Ken Griffin's Citadel Advisors (894K shares, $4.9M), Two Sigma Investments (669K shares, $3.6M), Izzy Englander's Millennium Management (97K shares, $526K), Cliff Asness's AQR Capital Management (49K shares, $264K).

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.